Scholarlink

<p>Clear cell renal cell carcinoma (ccRCC) is characterized by metabolic reprogramming and epigenetic dysregulation, primarily attributable to the loss of the Von Hippel-Lindau(VHL) gene and the resulting stabilization of HIF.Its metabolism is predominantly driven by the Warburg effect. However, metabolic patterns vary both across different tumors and within individual tumors.Histone lactylation is a recently discovered epigenetic mark linking glycolysis-derived lactate to gene expression.Lactate accumulation drives histone lactylation, thereby regulating the expression of genes involved in tumor progression and other malignant phenotypes.The interplay between metabolic diversity and histone modifications shapes distinct tumor phenotypes and their microenvironments.Finally, emerging therapies—including HIF-2α inhibitors, metabolic enzyme inhibitors, and epigenetic regulators—are introduced along with their potential use in combination with immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanisms and therapeutic implications of metabolic heterogeneity and histone lactylation in clear cell renal cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Jinhu Ma,
  • Ziyang Qiang,
  • Wenhao Xie,
  • Liang Jiao,
  • Yanxiong Wang,
  • Lin Mi,
  • Zhangjie Yang,
  • Guojun Chen

摘要

Clear cell renal cell carcinoma (ccRCC) is characterized by metabolic reprogramming and epigenetic dysregulation, primarily attributable to the loss of the Von Hippel-Lindau(VHL) gene and the resulting stabilization of HIF.Its metabolism is predominantly driven by the Warburg effect. However, metabolic patterns vary both across different tumors and within individual tumors.Histone lactylation is a recently discovered epigenetic mark linking glycolysis-derived lactate to gene expression.Lactate accumulation drives histone lactylation, thereby regulating the expression of genes involved in tumor progression and other malignant phenotypes.The interplay between metabolic diversity and histone modifications shapes distinct tumor phenotypes and their microenvironments.Finally, emerging therapies—including HIF-2α inhibitors, metabolic enzyme inhibitors, and epigenetic regulators—are introduced along with their potential use in combination with immunotherapy.